Clinical Trial Update: Comparative Study of BAT1806 to RoActemra® in Rheumatoid Arthritis Patients With Inadequate Response to Methotrexate [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing BAT1806 to RoActemra in rheumatoid arthritis patients with inadequate response to methotrexate has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• BAT1806 (tocilizumab biosimilar)
• RoActemra (tocilizumab)

Snippet

Sponsor: Bio-Thera Solutions | Conditions: Rheumatoid Arthritis | Phase 3 | Status: COMPLETED